A Single- and Multiple Ascending-Dose, Randomized, Double-Blind, Placebo-Controlled Study in Two Single-Center Study Parts to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5285119 Following Oral Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Balovaptan (Primary)
- Indications Autistic disorder
- Focus Adverse reactions
- Sponsors Roche
- 23 May 2013 Actual end date changed from Oct 2012 to Jul 2012 as reported by ClinicalTrials.gov.
- 15 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.